{
  "guideline": {
    "id": "PA166262321",
    "name": "Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1",
    "source": "CPIC",
    "version": 4,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262321",
    "relatedChemicals": [
      {
        "id": "PA134308647",
        "name": "rosuvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA390",
        "name": "ATP binding cassette subfamily G member 2 (Junior blood group)",
        "symbol": "ABCG2"
      },
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298488",
      "name": "Recommendation PA166298488",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061090,
        "html": "<p>Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298466",
      "name": "Recommendation PA166298466",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061068,
        "html": "<p>Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298479",
      "name": "Recommendation PA166298479",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061081,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298474",
      "name": "Recommendation PA166298474",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061076,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298487",
      "name": "Recommendation PA166298487",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061089,
        "html": "<p>Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298492",
      "name": "Recommendation PA166298492",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061094,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg. ABCG2 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298470",
      "name": "Recommendation PA166298470",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061072,
        "html": "<p>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298483",
      "name": "Recommendation PA166298483",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061085,
        "html": "<p>Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298476",
      "name": "Recommendation PA166298476",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061078,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298489",
      "name": "Recommendation PA166298489",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061091,
        "html": "<p>Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298467",
      "name": "Recommendation PA166298467",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061069,
        "html": "<p>Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298484",
      "name": "Recommendation PA166298484",
      "population": "general",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061086,
        "html": "<p>n/a</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298475",
      "name": "Recommendation PA166298475",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061077,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298480",
      "name": "Recommendation PA166298480",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061082,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298471",
      "name": "Recommendation PA166298471",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061073,
        "html": "<p>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298468",
      "name": "Recommendation PA166298468",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061070,
        "html": "<p>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt; 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298490",
      "name": "Recommendation PA166298490",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061092,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298477",
      "name": "Recommendation PA166298477",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061079,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298472",
      "name": "Recommendation PA166298472",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061074,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298485",
      "name": "Recommendation PA166298485",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061087,
        "html": "<p>Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.</p>\n"
      },
      "implications": [
        "ABCG2: Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298481",
      "name": "Recommendation PA166298481",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061083,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg. ABCG2 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298469",
      "name": "Recommendation PA166298469",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061071,
        "html": "<p>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298491",
      "name": "Recommendation PA166298491",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061093,
        "html": "<p>Based on SLCO1B1 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: n/a",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298465",
      "name": "Recommendation PA166298465",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061067,
        "html": "<p>Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298478",
      "name": "Recommendation PA166298478",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061080,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298473",
      "name": "Recommendation PA166298473",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061075,
        "html": "<p>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298486",
      "name": "Recommendation PA166298486",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA134308647",
          "name": "rosuvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061088,
        "html": "<p>Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "ABCG2: Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "version": "2024-03-25-16-13"
}